← Evidence library

BIB_070

Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma. Lancet 2022;399:1718–1729. KEYNOTE-716. [Tasks: L, 17] Tier: 2 Grade: A Retrieved: 2026-05-06

Evidence grade

A

Tier

2

Cited by tasks

L, 17

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_070/findings.md (research corpus). This page is a short context summary — not individualised medical advice.